Rheumatology

News Roundup: Amneal's Bevacizumab Biosimilar, Originator Pricing Impact, and More

June 18th 2021

By Tony Hagen

Amneal Pharmaceuticals develops its biosimilar pipeline with mAbxience, Xcenda estimates biosimilar effect on originator pricing, and Magellan Rx Management touts oncology biosimilars savings.

Alvotech Achieves Milestone in Bid to Capture Adalimumab Share

June 18th 2021

By Tony Hagen

Getting to the stage where clinical data on interchangeability are reportable to the FDA is a key milestone in Alvotech’s bid to get its high-concentration adalimumab biosimilar approved and on the market.

Survey: European Union Needs to Fine-tune Its Biosimilars Procurement

June 16th 2021

By Tony Hagen

The “winner-takes-all” tender process for biosimilar procurement in the European Union runs the risk of driving competitors out of the market, authors of a new survey contend.

Alvotech Commercial Officer Discusses Biosimilar Marketing Strategy

June 15th 2021

Product differentiation, global partners, and a large suite of biosimilars in development are ways that Reykjavik, Iceland-based Alvotech expects to stay ahead of the competition.

Celltrion Reports Positive Real-World Findings for Truxima in DLBCL

June 14th 2021

By Tony Hagen

Postmarketing retrospective studies of the rituximab biosimilar (CT-P10, Truxima) demonstrated comparable safety and efficacy for treatment of diffuse large B-cell lymphoma (DLBCL).

Opinion: Biosimilars Offer Savings and Access for US Patients

June 12th 2021

By Meaghan Smith

In this column, officials from the Biosimilars Forum and Xcenda discuss how biosimilar competition has lowered prices of originator biologics and improved patient access.

Part 2: Panelists Advise Patterning Guidelines on International Standards

June 11th 2021

In part 2 of this panel discussion, 3 experts on India’s biologics industry discuss whether biosimilars can be produced affordably in the country and ways of improving the industry’s image.

Matrix Report Identifies Shortcomings of US Patent System

June 10th 2021

By Tony Hagen

The European Union makes it far more difficult to obtain patents on biologics, reducing the likelihood of patent “thickets” that stifle competition, the Matrix Global Advisors report states.

Part 1: Panelists Suggest More Groundwork Is Needed for Indian Biologics to Achieve Global Market Access

June 9th 2021

In part 1 of this panel discussion, 3 experts on India’s biologics industry explain what’s missing from current biosimilar regulation and what the country needs to do for its products to compete internationally.

Bio-Thera Moves Golimumab Candidate Into Phase 3 Trial

June 8th 2021

By Tony Hagen

Bio-Thera has set up a psoriatic arthritis clinical trial for BAT2506, which references Simponi.